2024
The Right Dose: Results of a Patient Advocate–Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life
Loeser A, Kim J, Peppercorn J, Burkard M, Niemierko A, Juric D, Kalinsky K, Rugo H, Glenn L, Hodgdon C, Maues J, Johnson S, Padron N, Parekh K, Lustberg M, Bardia A. The Right Dose: Results of a Patient Advocate–Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life. JCO Oncology Practice 2024, 20: 972-983. PMID: 38518184, DOI: 10.1200/op.23.00539.Peer-Reviewed Original ResearchMetastatic breast cancerTreatment-related side effectsSide effectsDose reductionBreast cancerLow dosesQuality of lifePhase I clinical trialFlexible dosing optionsMaximum tolerated doseDose of drugCourse of therapyIndividual doses of drugsCourse of treatmentPatient-physician discussionsPrescribed doseTolerated doseTargeted therapyDosing optionsAlternative dosingMedical oncologistsDose initiationHigh dosesImprove patient well-beingEffective treatment
2023
Evolution of predictive risk factor analysis for chemotherapy-related toxicity
Hertz D, Lustberg M, Sonis S. Evolution of predictive risk factor analysis for chemotherapy-related toxicity. Supportive Care In Cancer 2023, 31: 601. PMID: 37773300, DOI: 10.1007/s00520-023-08074-x.Peer-Reviewed Original ResearchConceptsTreatment-related toxicityBiomarker discovery approachClinical practiceTaxane-induced peripheral neuropathyChemotherapy-related toxicitySame treatment regimenMaximum treatment benefitRisk factor analysisPrecision oncology treatmentsToxicity riskPeripheral neuropathyTreatment regimenSimilar patientsToxicity predictorsTreatment benefitPharmacogenetic predictorsOncology treatmentSide effectsTherapeutic outcomesCancer treatmentMinimal toxicityIntegrated biomarkersGermline genomicsBiomarker sciencePatientsTargeting a xenobiotic transporter to ameliorate vincristine-induced sensory neuropathy
Li Y, Drabison T, Nepal M, Ho R, Leblanc A, Gibson A, Jin Y, Yang W, Huang K, Uddin M, Chen M, DiGiacomo D, Chen X, Razzaq S, Tonniges J, McTigue D, Mims A, Lustberg M, Wang Y, Hummon A, Evans W, Baker S, Cavaletti G, Sparreboom A, Hu S. Targeting a xenobiotic transporter to ameliorate vincristine-induced sensory neuropathy. JCI Insight 2023, 8: e164646. PMID: 37347545, PMCID: PMC10443802, DOI: 10.1172/jci.insight.164646.Peer-Reviewed Original ResearchConceptsPeripheral neurotoxicitySide effectsDose-limiting peripheral neurotoxicityDorsal root ganglion neuronsMultiple malignant diseasesUptake of vincristineAction potential amplitudeEffective preventative treatmentMechanical allodyniaThermal hyperalgesiaSensory neuropathyGanglion neuronsMalignant diseasePlasma levelsDose selectionVincristine accumulationUntargeted metabolomics analysisAntitumor effectsClinical developmentPotential amplitudePreventative treatmentNeuronal transporterNeuronal morphologyVincristinePharmacological inhibitionIdentifying factors that influence the decision to reduce, delay, or discontinue treatment due to chemotherapy-induced peripheral neuropathy: A community-centered approach.
Radwan R, Hertz D, Hickey E, Vachhani H, Lustberg M, Bridges J, Sabo R, Sheppard V, Salgado T. Identifying factors that influence the decision to reduce, delay, or discontinue treatment due to chemotherapy-induced peripheral neuropathy: A community-centered approach. Journal Of Clinical Oncology 2023, 41: e13123-e13123. DOI: 10.1200/jco.2023.41.16_suppl.e13123.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyMetastatic breast cancerPeripheral neuropathyTreatment alterationsTreatment effectivenessMBC patientsCIPN symptomsMedical oncologistsDiscontinue treatmentClinical guidelinesOncology cliniciansCommunity-centered approachEffective therapyBreast cancerChemotherapy agentsTreatment decisionsPatient prioritiesPatient's perspectiveDose reductionAlternative treatmentOptimize outcomesPatientsSide effectsTreatment planHealthcare providersHair loss during and after breast cancer therapy
Rose L, Lustberg M, Ruddy K, Cathcart-Rake E, Loprinzi C, Dulmage B. Hair loss during and after breast cancer therapy. Supportive Care In Cancer 2023, 31: 186. PMID: 36826602, DOI: 10.1007/s00520-023-07634-5.Peer-Reviewed Original ResearchConceptsTreatment optionsHair lossDistressing side effectsChemotherapy-induced alopeciaCancer therapyBreast cancer therapyEndocrine therapyMajor surgeryPatient counselingTelogen effluviumBreast cancerBreast oncologistsSide effectsPrevention strategiesAlopeciaTherapyChemotherapyPatientsSurgeryOncologistsOptionsEtiologyCancerRetrospective cohort study of scalp cooling in breast cancer patients
Rose L, Schnell P, Radcliff L, Lustberg M, Dulmage B. Retrospective cohort study of scalp cooling in breast cancer patients. Supportive Care In Cancer 2023, 31: 118. PMID: 36645520, DOI: 10.1007/s00520-022-07562-w.Peer-Reviewed Original ResearchConceptsScalp coolingChemotherapy regimenPatient ageInsurance statusRetrospective cohort studyCommon side effectsRetrospective chart reviewNon-white patientsBreast cancer patientsStage of cancerQuality of lifeChart reviewCohort studyWhite patientsPatient's likelihoodChemotherapy infusionCancer patientsTreatment optionsOncology settingBreast cancerPatient decisionSide effectsPatientsTreatment planHealthcare providers
2022
Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity
Nepal M, Taheri H, Li Y, Talebi Z, Uddin M, Jin Y, DiGiacomo D, Gibson A, Lustberg M, Hu S, Sparreboom A. Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity. Cancer Research Communications 2022, 2: 1334-1343. PMID: 36506732, PMCID: PMC9730833, DOI: 10.1158/2767-9764.crc-22-0172.Peer-Reviewed Original ResearchConceptsDRG neuronsPeripheral neurotoxicitySide effectsOxaliplatin-Induced Peripheral NeurotoxicityOxaliplatin-based regimensOxaliplatin-based treatmentPharmacokinetics of oxaliplatinEffect of duloxetineMouse DRG neuronsWild-type miceCytotoxicity of oxaliplatinConcentration-dependent mannerColorectal cancerCancer patientsPlasma levelsOIPNPlasma pharmacokineticsDuloxetinePrevention strategiesTherapeutic candidateOxaliplatinTumor cell linesTranslational feasibilityMiceComplete protection
2021
Effects of plant-based versus marine-based omega-3 fatty acids and sucrose on brain and liver fatty acids in a mouse model of chemotherapy
Ormiston K, Gaudier-Diaz MM, TinKai T, Fitzgerald J, Cole RM, Andridge R, Lustberg M, DeVries AC, Orchard T. Effects of plant-based versus marine-based omega-3 fatty acids and sucrose on brain and liver fatty acids in a mouse model of chemotherapy. Nutritional Neuroscience 2021, 25: 2650-2658. PMID: 34772330, PMCID: PMC9095756, DOI: 10.1080/1028415x.2021.1998296.Peer-Reviewed Original ResearchConceptsAlpha-linolenic acidDietary alpha-linolenic acidBrain PUFAsMouse modelDocosahexaenoic acidEicosapentaenoic acidLiver PUFABrain nOmega-3 fatty acidsChemotherapy-treated miceHigh ALA dietLow ALA intakeBrain fatty acidsUseful surrogate markerFatty acidsLiver docosahexaenoic acidToxic side effectsLiver fatty acidALA intakeNeurotrophic markersALA dietDHA dietSurrogate markerLower brainSide effectsLimited benefit and high financial burden of drugs used to manage cancer-associated anorexia/cachexia syndrome (CACS).
Gupta A, Nshuti L, Grewal U, Sedhom R, Parsons H, Blaes A, Virnig B, Lustberg M, Subbiah I, Nipp R, Dy S, Dusetzina S. Limited benefit and high financial burden of drugs used to manage cancer-associated anorexia/cachexia syndrome (CACS). Journal Of Clinical Oncology 2021, 39: 55-55. DOI: 10.1200/jco.2020.39.28_suppl.55.Peer-Reviewed Original ResearchPrescription drug coverageAnorexia/cachexia syndromeDrug coveragePocket costsRisk/benefit ratioPatient-clinician discussionsSupportive care guidelinesFinancial burdenList of drugsCost of drugsUse of drugsHigh financial burdenEnd of lifeCachexia syndromeCare guidelinesUnwanted side effectsGeneric olanzapineSide effectsClinical practiceCertain drugsMultiple drugsStudy authorsBenefit ratioDrugsLimited benefitReal-world data on usage of scalp cooling for chemotherapy associated alopecia in the United States.
Williams N, Paxman R, Thornhill E, Kassem M, Grimm M, Dulmage B, Cathcart-Rake E, Ruddy K, Pariser A, Gatti-Mays M, Cherian M, VanDeusen J, Stover D, Sardesai S, Wesolowski R, Ramaswamy B, Loprinzi C, Lustberg M. Real-world data on usage of scalp cooling for chemotherapy associated alopecia in the United States. Journal Of Clinical Oncology 2021, 39: e18739-e18739. DOI: 10.1200/jco.2021.39.15_suppl.e18739.Peer-Reviewed Original ResearchScalp coolingNational Comprehensive Cancer NetworkMedical Oncology guidelinesComprehensive Cancer NetworkMajority of patientsOncology guidelinesCategory 2ABreast cancerHair lossCancer NetworkSide effectsChemotherapyLargest reportPatientsReal-world useOlder adultsScalpEuropean SocietyFurther studiesAlopeciaCancerDescriptive statisticsGenitourinaryLungGynecologyEmerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy
Li Y, Lustberg MB, Hu S. Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. Cancers 2021, 13: 766. PMID: 33673136, PMCID: PMC7918689, DOI: 10.3390/cancers13040766.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyPeripheral neuropathyPathogenesis of CIPNTreatment of CIPNFirst-line chemotherapeutic agentNon-pharmacological therapeuticsCommon adverse eventsNon-pharmacological strategiesQuality of lifeAdverse eventsClinical outcomesCancer survivorsEffective intervention strategiesClinical trialsSide effectsChemotherapeutic agentsEffective interventionsVinca alkaloidsNew targetsIntervention strategiesNeuropathyPrior failureClinical researchersPlatinum compoundsTherapeuticsAdverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias
Schnell PM, Lustberg MB, Henry NL. Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias. JNCI Cancer Spectrum 2021, 5: pkab018. PMID: 33842832, PMCID: PMC8023424, DOI: 10.1093/jncics/pkab018.Peer-Reviewed Original ResearchConceptsPatient-perceived benefitsAdverse eventsBrief Pain Inventory-Short FormAromatase Inhibitor–Associated ArthralgiaDuloxetine-treated patientsOriginal primary outcomeDouble-blind trialLow-grade toxicityEffect of duloxetineSubgroup of patientsAverage painComparable patientsAppropriate patientsPrimary outcomeMusculoskeletal symptomsBreast cancerPlaceboDuloxetineSide effectsFunctional assessmentPatientsSecondary analysisFavorable effectTreatmentPerceptions of benefitsTargeting OCT3 attenuates doxorubicin-induced cardiac injury
Huang KM, Thomas M, Magdy T, Eisenmann ED, Uddin ME, DiGiacomo DF, Pan A, Keiser M, Otter M, Xia SH, Li Y, Jin Y, Fu Q, Gibson AA, Bonilla IM, Carnes CA, Corps KN, Coppola V, Smith SA, Addison D, Nies AT, Bundschuh R, Chen T, Lustberg MB, Wang J, Oswald S, Campbell MJ, Yan PS, Baker SD, Hu S, Burridge PW, Sparreboom A. Targeting OCT3 attenuates doxorubicin-induced cardiac injury. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2020168118. PMID: 33495337, PMCID: PMC7865186, DOI: 10.1073/pnas.2020168118.Peer-Reviewed Original ResearchConceptsOrganic cation transporter 3Cardiac injuryCardiovascular functionSide effectsTranslational relevanceCalcium-binding proteins S100A8Irreversible cardiac injuryCurrent preventative strategiesPotential translational relevanceCardiac damagePlasma levelsCardiac accumulationBreast cancerAntitumor effectsPharmacological targetingPreventative strategiesModest protectionProteins S100A8Critical transporterTransporter 3Pharmacological inhibitorsOverexpression modelIntervention strategiesDoxorubicinCardiotoxicity
2020
Differential Contribution of Neuronal Uptake Transporters to Oxaliplatin Peripheral Neurotoxicity
Huang K, Leblanc A, Alberti P, Sprowl J, Wang J, Lustberg M, Cavaletti G, Hu S, Sparreboom A. Differential Contribution of Neuronal Uptake Transporters to Oxaliplatin Peripheral Neurotoxicity. The FASEB Journal 2020, 34: 1-1. DOI: 10.1096/fasebj.2020.34.s1.03083.Peer-Reviewed Original ResearchDorsal root gangliaPeripheral neurotoxicityColorectal cancerOxaliplatin-induced peripheral neurotoxicityVon Frey hair testChronic peripheral neurotoxicityOxaliplatin-induced neurotoxicityVivo cultureColorectal cancer cellsWild-type ratsEx vivo cultureOxaliplatin therapyAfford neuroprotectionObserved neuroprotectionNeurological injuryRoot gangliaOxaliplatin accumulationSystemic clearanceConventional chemotherapyGlial cellsPreclinical modelsSprague-DawleySensory neuronsMouse modelSide effects
2016
Natural history of postural instability in breast cancer patients treated with taxane-based chemotherapy: A pilot study
Monfort S, Pan X, Patrick R, Singaravelu J, Loprinzi C, Lustberg M, Chaudhari A. Natural history of postural instability in breast cancer patients treated with taxane-based chemotherapy: A pilot study. Gait & Posture 2016, 48: 237-242. PMID: 27341530, PMCID: PMC4969166, DOI: 10.1016/j.gaitpost.2016.06.011.Peer-Reviewed Original ResearchConceptsBreast cancer patientsTaxane-based chemotherapyCancer patientsPostural instabilityChemotherapy cyclesBalance impairmentNatural historyCOP excursionPilot studyCoP ellipse areaSubsequent chemotherapy cyclesFirst chemotherapy cycleEyes-closed conditionTaxane exposureTaxane infusionEllipse areaOncology clinicConfidence ellipse areaPatient populationChemotherapy treatmentAdverse symptomsBreast cancerBaseline valuesEffective treatmentSide effects
2011
Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
Berger M, Dunlea L, Rettig A, Lustberg M, Phillips G, Shapiro C. Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Supportive Care In Cancer 2011, 20: 1991-1997. PMID: 22089428, PMCID: PMC3411299, DOI: 10.1007/s00520-011-1303-9.Peer-Reviewed Original ResearchConceptsInfusion hypersensitivity reactionPaclitaxel-based chemotherapyHypersensitivity reactionsRescue medicationPaclitaxel dosesSecond doseDoses of paclitaxelBreast cancer patientsUse of paclitaxelPotential unwanted side effectsConclusionsIn patientsPrimary endpointSubsequent dosesUnwanted side effectsCancer patientsPremedicationSide effectsPatientsSolid tumorsDoses 3MedicationsChemotherapyDosesHypersensitivityDose